Welcome to LookChem.com Sign In|Join Free
  • or
4-amino-4'-(trifluoromethyl)-3-biphenylcarbonitrile is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

405520-49-2

Post Buying Request

405520-49-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

405520-49-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 405520-49-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,0,5,5,2 and 0 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 405520-49:
(8*4)+(7*0)+(6*5)+(5*5)+(4*2)+(3*0)+(2*4)+(1*9)=112
112 % 10 = 2
So 405520-49-2 is a valid CAS Registry Number.

405520-49-2Relevant academic research and scientific papers

DIPHENYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS OR BKCA CHANNEL MODULATORS

-

Page/Page column 15, (2008/06/13)

The present invention relates to novel diphenylurea derivatives of formula (I) useful as chloride channel blockers or BKCa channel modulators. In other aspects the invention relates to the use of these compounds in a method for therapy, and to

Novel ATP-competitive kinesin spindle protein inhibitors

Parrish, Cynthia A.,Adams, Nicholas D.,Auger, Kurt R.,Burgess, Joelle L.,Carson, Jeffrey D.,Chaudhari, Amita M.,Copeland, Robert A.,Diamond, Melody A.,Donatelli, Carla A.,Duffy, Kevin J.,Faucette, Leo F.,Finer, Jeffrey T.,Huffman, William F.,Hugger, Erin D.,Jackson, Jeffrey R.,Knight, Steven D.,Luo, Lusong,Moore, Michael L.,Newlander, Ken A.,Ridgers, Lance H.,Sakowicz, Roman,Shaw, Antony N.,Sung, Chiu-Mei M.,Sutton, David,Wood, Kenneth W.,Zhang, Shu-Yun,Zimmerman, Michael N.,Dhanak, Dashyant

, p. 4939 - 4952 (2008/03/11)

Kinesin spindle protein (KSP), an ATPase responsible for spindle pole separation during mitosis that is present only in proliferating cells, has become a novel and attractive anticancer target with potential for reduced side effects compared to currently available therapies. We report herein the discovery of the first known ATP-competitive inhibitors of KSP, which display a unique activity profile as compared to the known loop 5 (L5) allosteric KSP inhibitors that are currently under clinical evaluation. Optimization of this series led to the identification of biphenyl sulfamide 20, a potent KSP inhibitor with in vitro antiproliferative activity against human cells with either wild-type KSP (HCT116) or mutant KSP (HCT116 D 130V). In a murine xenograft model with HCT116 D130V tumors, 20 showed significant antitumor activity following intraperitoneal dosing, providing in vivo proof-of-principle of the efficacy of an ATP-competitive KSP inhibitor versus tumors that are resistant to the other known KSP inhibitors.

Compounds, compositions and methods

-

Page/Page column 16, (2010/11/27)

Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.

Compounds, Compositions and Methods

-

Page/Page column 16, (2010/11/28)

Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.

COMPOUNDS, COMPOSITIONS AND METHODS

-

Page/Page column 37-38, (2010/11/24)

Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.

DIPHENYLUREA DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS

-

Page/Page column 40, (2008/06/13)

The present invention relates to the medical use of a certain group of diphenyl urea derivatives as potassium channel blockers for treating cardiovascular diseases, an obstructive or inflammatory airway disease, urinary incontinence, psychosis, epilepsy o

DIPHENYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS

-

Page 15, (2008/06/13)

The present invention relates to novel diphenylurea derivatives useful as chloride channel blockers. In other aspects the invention relates to the use of these compounds in a method for therapy, and to pharmaceutical compositions comprising the compounds

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 405520-49-2